| NCT00756717 | Breast Cancer | Drug: MK-0752 | Loyola University|Merck Sharp & Dohme Corp. | | 2008-05-01 | 2015-04-01 |
| NCT00645333 | Metastatic Breast Cancer | Drug: MK-0752, Docetaxel, Pegfilgrastim | University of Michigan Cancer Center|Baylor College of Medicine|Ohio State University|Dana-Farber Cancer Institute|Weill Medical College of Cornell University|Merck Sharp & Dohme Corp. | Phase 1|Phase 2 | 2008-03-01 | 2014-02-24 |
| NCT00572182 | Brain and Central Nervous System Tumors | Drug: MK-0752 | Pediatric Brain Tumor Consortium|National Cancer Institute (NCI) | Phase 1 | 2008-07-01 | 2012-03-02 |
| NCT01295632 | Advanced Cancer | Drug: ridaforolimus|Drug: MK-0752|Drug: MK-2206 | Merck Sharp & Dohme Corp. | Phase 1 | 2011-02-01 | 2015-08-26 |
| NCT01243762 | Neoplasms Malignant | Drug: dalotuzumab + MK-2206|Drug: dalotuzumab + MK-0752|Drug: Dalotuzumab + MK-8669 (ridaforolimus) | Merck Sharp & Dohme Corp. | Phase 1 | 2010-11-01 | 2015-01-29 |
| NCT00803894 | Healthy | Drug: MK0752|Drug: Comparator: MK0752.|Drug: Comparator: Placebo | Merck Sharp & Dohme Corp. | Phase 1 | 2008-12-01 | 2016-06-16 |
| NCT01098344 | Pancreatic Cancer | Drug: Notch signaling pathway inhibitor MK0752|Drug: gemcitabine hydrochloride|Other: imaging biomarker analysis|Other: laboratory biomarker analysis|Other: pharmacological study | Cancer Research UK | Phase 1 | 2010-04-01 | 2015-10-13 |
| NCT00106145 | Advanced Breast Cancer|Other Solid Tumors | Drug: Comparator: MK0752, Notch Inhibitor|Drug: Comparator: MK0752, Notch Inhibitor - 450 mg|Drug: Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off|Drug: Comparator: MK0752, Notch Inhibitor - 1 day on, 6 off|Drug: Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off 350 mg | Merck Sharp & Dohme Corp. | Phase 1 | 2005-04-01 | 2015-01-29 |
| NCT00100152 | Leukemia, Lymphoblastic, Acute, T-cell|Myelogenous Leukemia|Chronic Lymphocytic Leukemia|Myelodysplastic Syndromes | Drug: MK0752, (Notch Inhibitor) | Merck Sharp & Dohme Corp. | Phase 1 | 2005-02-01 | 2015-05-25 |
